Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

JazzPharmaceuticals

More Like This

PR Newswire associated0

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

PR Newswire associated0

Jazz Pharmaceuticals to Participate in Upcoming Investor Events

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA

Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA

PR Newswire associated0

Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results

PR Newswire associated0

Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients

PR Newswire associated0

Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference